Immunosuppressants drugs for COVID-19: living meta-analysis of clinical studies

Table Graph

Immunosuppressants drugs - versus control - for COVID 19 hospitalized pdf xlsx method abbreviations

Outcome	Relative effect 95%CI	Trt. better when	I2	k (RCT/OBS)	Bayesian probability	Overall ROB	Publication bias	Degree of certainty	Endpoint importance	Published MA
efficacy endpoints 00
death D28	0.76 [0.65, 0.87]	< 1	14%	23 studies (23/-)	100.0 %	some concern	critical	moderate	crucial	-
death or transfer to ICU	0.97 [0.50, 1.88]	< 1	0%	1 study (1/-)	53.6 %	NA	not evaluable		crucial	-
deaths	0.81 [0.75, 0.88]	< 1	4%	34 studies (34/-)	100.0 %	some concern	critical	moderate	crucial	-
deaths (time to event analysis only)	0.76 [0.60, 0.95]	< 1	34%	7 studies (7/-)	99.1 %	some concern	not evaluable	moderate	crucial	-
clinical deterioration	0.71 [0.52, 0.98]	< 1	61%	10 studies (10/-)	98.2 %	some concern	critical	moderate	important	-
clinical improvement	1.22 [1.11, 1.34]	> 1	9%	12 studies (12/-)	100.0 %	low	low	high	important	-
clinical improvement (14-day)	1.31 [1.13, 1.52]	> 1	0%	3 studies (3/-)	100.0 %	low	not evaluable	high	important	-
clinical improvement (28-day)	1.33 [0.95, 1.87]	> 1	0%	4 studies (4/-)	95.3 %	some concern	not evaluable	moderate	important	-
clinical improvement (time to event analysis only)	1.14 [1.03, 1.27]	> 1	0%	4 studies (4/-)	99.4 %	low	not evaluable	high	important	-
death or ventilation	0.83 [0.77, 0.91]	< 1	18%	13 studies (13/-)	100.0 %	some concern	low	moderate	important	-
hospital discharge	1.05 [0.88, 1.25]	> 1	13%	2 studies (2/-)	70.0 %	some concern	not evaluable	moderate	important	-
mechanical ventilation	0.81 [0.70, 0.93]	< 1	1%	9 studies (9/-)	99.8 %	some concern	not evaluable	moderate	important	-
ICU admission	0.85 [0.49, 1.49]	< 1	57%	3 studies (3/-)	71.2 %	some concern	not evaluable	moderate	non important	-
recovery	1.30 [0.64, 2.66]	> 1	9%	2 studies (2/-)	76.5 %	low	not evaluable	high	non important	-
safety endpoints 00
related AE (TRAE)	1.26 [0.14, 11.07]	< 1	0%	2 studies (2/-)	41.9 %	some concern	not evaluable	moderate	important	-
serious adverse events	0.94 [0.78, 1.13]	< 1	0%	10 studies (10/-)	74.7 %	some concern	critical	moderate	important	-
superinfection	0.50 [0.32, 0.79]	< 1	0%	1 study (1/-)	99.8 %	NA	not evaluable		important	-
adverse events	1.32 [0.92, 1.91]	< 1	57%	9 studies (9/-)	6.7 %	some concern	not evaluable	moderate	non important	-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

Immunosuppressants drugs - versus control - for COVID 19 hospitalized pdf xlsx method abbreviations

efficacy endpoints 00

safety endpoints 00